On October 18, 2024, Dr. Benfong Phumalaisi, Minister of Health of the Lao People's Democratic Republic, Dr. Bensho Khehovong, Director of the Food and Drug Administration, and Mrs. Sunanta Suwanrasi, Dean of the School of Pharmacy at the University of Health Sciences, and a group of 11 people visited the company's Beijing R&D Center. Mr. Wang Manchao, General Manager of the company, and the Beijing R&D technical team warmly received Minister Benfong and his party.

At the subsequent negotiation and exchange meeting, General Manager Wang Manchao first expressed a warm welcome to Minister Benfeng and the leaders of Laos on behalf of the company, and also stated that the company's medical beauty raw materials and products will be deployed globally, especially in ASEAN, With the layout of the “Belt and Road” and BRICS countries, Laos, as one of the ASEAN member states, hopes to obtain the first relevant product registration certificate in Laos, including recombinant type III collagen water light, filler and recombinant type A botulinum toxin, and build Laos into a bridgehead for the company's products to enter ASEAN.

Then Dr. Zuo Tao, the company's technical director, gave a detailed introduction to the company's current research and development progress and achievements in the field of medical beauty, and led Minister Ben Feng and his party to visit the Beijing R&D Center.

Finally, Minister Benfeng affirmed the company's R&D strength in applying synthetic biology technology in medical beauty raw materials and products, and showed great interest in existing recombinant type III collagen and recombinant botulinum toxin and other related products. He said that the market prospects of these products in ASEAN are very huge, and hoped that the company could go to Laos to produce and register related products, and go to ASEAN through Laos.